Alessandra Curioni-Fontecedro, MD is the Head of Medical Thoracic Oncology, Research Group Leader, and Chair of the Expert Group Immuno-Oncology at the University Hospital of Zurich, Switzerland. In addition, she is the current Director of the Lung Cancer Program at the European School of Oncology (ESO), Board Member of the Federal Institute for Measurements in Switzerland (METAS), and vice president of the Immuno-oncology and New anti-cancer treatments working groups within the Swiss Group for Clinical Cancer Research (SAKK). At ESMO, she is faculty member of the group Investigational Immunotherapy and editor in Chief of the ESMO Daily reporter journal.
Dr. Curioni-Fontecedro’s was scientific physician at the Laboratory of Immuno-Oncology of the University Hospital in Zurich (Switzerland) and at the laboratory of Experimental Immunology of the University of Zurich. Since 2018, she leads the lab of Translational Oncology at the University Hospital in Zurich, where her research focus is evaluating new combinatorial treatments and their underlying mechanisms of action in the treatment of mesothelioma and lung cancer.
Dr. Curioni-Fontecedro obtained her medical degree from University Campus Bio-Medico (UCBM) Rome, Italy. She did her MD at the Department of Molecular Biology of the University of Zurich and then went on to residencies in Internal Medicine, Oncology, and Thoracic Surgery at the University Hospital of Zurich.